In this study, we evaluated the antitumor effects of local CpG-Stat3 siRNA treatment at tumor sites to boost the antitumor effects of CTLA4 and/or PD-1 antibody systemic treatments in the A20 mouse lymphoma model and the B16 melanoma model. The gene discussed is STAT3; the disease is neoplasm.